Literature DB >> 26158047

Magnetization-prepared rapid acquisition with gradient echo magnetic resonance imaging signal and texture features for the prediction of mild cognitive impairment to Alzheimer's disease progression.

Antonio Martinez-Torteya1, Juan Rodriguez-Rojas1, José M Celaya-Padilla1, Jorge I Galván-Tejada1, Victor Treviño2, Jose Tamez-Peña2.   

Abstract

Early diagnoses of Alzheimer's disease (AD) would confer many benefits. Several biomarkers have been proposed to achieve such a task, where features extracted from magnetic resonance imaging (MRI) have played an important role. However, studies have focused exclusively on morphological characteristics. This study aims to determine whether features relating to the signal and texture of the image could predict mild cognitive impairment (MCI) to AD progression. Clinical, biological, and positron emission tomography information and MRI images of 62 subjects from the AD neuroimaging initiative were used in this study, extracting 4150 features from each MRI. Within this multimodal database, a feature selection algorithm was used to obtain an accurate and small logistic regression model, generated by a methodology that yielded a mean blind test accuracy of 0.79. This model included six features, five of them obtained from the MRI images, and one obtained from genotyping. A risk analysis divided the subjects into low-risk and high-risk groups according to a prognostic index. The groups were statistically different ([Formula: see text]). These results demonstrated that MRI features related to both signal and texture add MCI to AD predictive power, and supported the ongoing notion that multimodal biomarkers outperform single-modality ones.

Entities:  

Keywords:  Alzheimer’s disease; magnetic resonance imaging biomarker; magnetization-prepared rapid acquisition with gradient echo; mild cognitive impairment; multimodal biomarker

Year:  2014        PMID: 26158047      PMCID: PMC4479020          DOI: 10.1117/1.JMI.1.3.031005

Source DB:  PubMed          Journal:  J Med Imaging (Bellingham)        ISSN: 2329-4302


  22 in total

1.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

Review 2.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population.

Authors:  Chris Hinrichs; Vikas Singh; Guofan Xu; Sterling C Johnson
Journal:  Neuroimage       Date:  2010-12-10       Impact factor: 6.556

Review 5.  A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Biol Psychiatry       Date:  2013-11-28       Impact factor: 13.382

Review 6.  Causative and susceptibility genes for Alzheimer's disease: a review.

Authors:  A Rocchi; S Pellegrini; G Siciliano; L Murri
Journal:  Brain Res Bull       Date:  2003-06-30       Impact factor: 4.077

Review 7.  Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Authors:  Harald Hampel; Katharina Bürger; Stefan J Teipel; Arun L W Bokde; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

8.  Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.

Authors:  K B Walhovd; A M Fjell; J Brewer; L K McEvoy; C Fennema-Notestine; D J Hagler; R G Jennings; D Karow; A M Dale
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

9.  Age-associated alterations in cortical gray and white matter signal intensity and gray to white matter contrast.

Authors:  D H Salat; S Y Lee; A J van der Kouwe; D N Greve; B Fischl; H D Rosas
Journal:  Neuroimage       Date:  2009-07-04       Impact factor: 6.556

10.  Automatic morphometry in Alzheimer's disease and mild cognitive impairment.

Authors:  Rolf A Heckemann; Shiva Keihaninejad; Paul Aljabar; Katherine R Gray; Casper Nielsen; Daniel Rueckert; Joseph V Hajnal; Alexander Hammers
Journal:  Neuroimage       Date:  2011-03-11       Impact factor: 6.556

View more
  4 in total

1.  Pioneers in Medical Imaging: Honoring the Memory of Robert F. Wagner.

Authors:  Kyle J Myers; Weijie Chen
Journal:  J Med Imaging (Bellingham)       Date:  2014-10

Review 2.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

3.  Benchmarking machine learning models for late-onset alzheimer's disease prediction from genomic data.

Authors:  Javier De Velasco Oriol; Edgar E Vallejo; Karol Estrada; José Gerardo Taméz Peña; The Alzheimer's Disease Neuroimaging Initiative
Journal:  BMC Bioinformatics       Date:  2019-12-16       Impact factor: 3.169

4.  Quality Reporting of Radiomics Analysis in Mild Cognitive Impairment and Alzheimer's Disease: A Roadmap for Moving Forward.

Authors:  So Yeon Won; Yae Won Park; Mina Park; Sung Soo Ahn; Jinna Kim; Seung Koo Lee
Journal:  Korean J Radiol       Date:  2020-10-30       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.